S-1 in Combination With Abraxane in Treating Cholangiocarcinoma
Phase II Study of Abraxane Plus S-1 as Second-line Treatment for Cholangiocarcinoma
This phase II study was designed to evaluate the efficacy and safety of S-1 plus Abraxane as second-line treatment for cholangiocarcinoma.
There are no standard second-line treatment for cholangiocarcinoma, new therapies are needed. The efficacy of S-1 as first-line treatment for cholangiocarcinoma was confirmed in several studies. The IMPACT study showed that Abraxane plus gemcitabine provide better survival than gemcitabine alone. Since cholangiocarcinoma displayed similar sensitivity to chemotherapy which was used in pancreatic carcinoma, we assume that S-1 plus Abraxane is effective and safe in treating cholangiocarcinoma.
S-1 plus Abraxane
Study Arms / Comparison Groups
S-1 plus Abraxane
Description: Patients will receive Abraxane at 100 mg/m2 X 3 doses on Days 1, 8. S-1 chemotherapy was given based on the body surface area, <1.25 m2: 80mg/day, 1.25~1.5 m2: 100mg/day, ≧1.5 m2: 120mg/day. Given orally twice daily for 14 days, followed by 7 days without treatment.
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Primary Completion Date
Inclusion Criteria: - Histologic or cytologic diagnosis of cholangiocarcinoma - Not eligible for curative surgery - Progressed after first-line gemcitabine-based chemotherapy - Eastern Cooperative Oncology Group (ECOG) performance status of 2 or better - No serious or uncontrolled concomitant medical illness - Adequate bone marrow function (absolute neutrophil count ≧1,500 ul, platelet count ≧90,000/ul), hemoglobin: > or equal to 8 mg/dL, total bilirubin: < or equal to 1.5 X institutional upper limit of normal, calculated creatinine clearance greater than or equal to 60 mL/min (calculated by the Cockcroft and Gault method). Exclusion Criteria: - Uncontrolled infection or severe active comorbid disease - Previous malignancy in the past five years, excluding nonmelanoma skin cancers and in situ cervical, bladder or uterine cancer - Pregnancy or lactating women
18 Years - 75 Years
Accepts Healthy Volunteers
Yuhong Li, MD, ,
Yuhong Li, MD, Principal Investigator, Sun Yat-sen University